Accéder au contenu
Merck

Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Atherosclerosis (2017-11-04)
Anna Wolska, Richard L Dunbar, Lita A Freeman, Masako Ueda, Marcelo J Amar, Denis O Sviridov, Alan T Remaley
RÉSUMÉ

Apolipoprotein C-II (apoC-II) is a small exchangeable apolipoprotein found on triglyceride-rich lipoproteins (TRL), such as chylomicrons (CM) and very low-density lipoproteins (VLDL), and on high-density lipoproteins (HDL), particularly during fasting. ApoC-II plays a critical role in TRL metabolism by acting as a cofactor of lipoprotein lipase (LPL), the main enzyme that hydrolyses plasma triglycerides (TG) on TRL. Here, we present an overview of the role of apoC-II in TG metabolism, emphasizing recent novel findings regarding its transcriptional regulation and biochemistry. We also review the 24 genetic mutations in the APOC2 gene reported to date that cause hypertriglyceridemia (HTG). Finally, we describe the clinical presentation of apoC-II deficiency and assess the current therapeutic approaches, as well as potential novel emerging therapies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Apolipoprotein C-II from human plasma, ≥95% (SDS-PAGE)